Continued innovation of proprietary cell-free cloning technology has improved synthesis success rates, enabling pricing as low as $0.15 per base pair. SAN CARLOS, Calif.--(BUSINESS WIRE)--Elegen, a ...

Elegen sets a new benchmark for clonal, cell-free synthetic DNA with ENFINIA, delivering unmatched length and accuracy from ...

Elegen has launched ENFINIA™ IVT Ready DNA, a cell-free gene synthesis platform that provides full-length linear DNA templates encoded poly(A) tails for in vitro transcription. The templates are ...

FARGO, N.D.--(BUSINESS WIRE)--Aldevron, a global leader in the production of DNA, RNA and protein, has launched its latest innovation, Alchemy™ cell-free DNA technology. This revolutionary technology ...

Elegen and Nutcracker Therapeutics launched a pilot program to demonstrate what they label the industry’s first fully synthetic, cell-free manufacturing platform for RNA-based personalized cancer ...

Powered by the company’s proprietary enzymatic synthesis platform and backed by the unique Ansa On-Time Guarantee, the new product allows scientists to design and obtain complete, error-free DNA ...

Johnson and Alistar competed as finalists in CU Boulder’s 2025 Lab Venture Challenge where their technology generated much interest from industry leaders. Access to DNA is crucial in many branches of ...

Elegen, a global leader in next-generation DNA manufacturing, and Nutcracker Therapeutics, a global leader in next-generation RNA design and manufacturing, today announced the launch of a pilot ...